Yvonne Commodore-Mensah, PhD, MHS, RN

So excited to hear @ycommodore.bsky.social discuss “Hypertension: Local & Global Interventions” at the PCNA Annual Symposium

The Cost of Cutting NIH Research: Voices from the Frontlines A candid conversation between a professor and a Ph.D. candidate about potential NIH funding cuts and their impact on the future of medical research.

The Cost of Cutting NIH Research: Voices from the Frontlines tradeoffs.org/2025/03/13/c.... Thank you @tradeoffs.org for the opportunity to reflect with Laura López.

The Link between CKD and CVD Discover the importance of early CKD testing and diagnosis to improve patient outcomes. Access our podcast series, toolkit, & educational resources for healthcare professionals.

Sweet… first set of pods dropped!!

I loved hosting the @ahascience.bsky.social podcast series: The Link between #CKD and #CVD #CKMSyndrome

Check out the link below for the pods and toolkit

professional.heart.org/en/education...

Though AHA may want to think twice about using my voice 🤷‍♂️😅

I’m grateful for all the wonderful memories created at #AHA24. Until we meet again at #AHA25 in #NOLA! @rantocran.bsky.social @bunmiogungbe.bsky.social @modeldoc.bsky.social

Likewise ! 😊

We now have @ycommodore.bsky.social discussing her work in LINKED-BP, an @ahascience.bsky.social health-Equity research network project

#AHA24 #AHAMeeting

Starting off strong with presentations from Drs Susmita Parashar, Yvonne Commodore-Mensah and Khadijah Breathett #AHA24 @ahascience.bsky.social

Dr. Keith Churchwell at the podium delivering the keynote at the opening session

Starting us off is Dr. Keith B. Churchwell, the president of the AHA #AHA24 @ahascience.bsky.social

We’re building on 100 years of hope this year at #AH24. The Centennial Experience captures 100 years of #cardiology history, make time for it this weekend at Scientific Sessions. Thank you for joining us and inspiring us into our second century.

🎥: @dramitkhera.bsky.social

BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg).

Watch this for one attendee’s take on the data.

Tirzepatide is another option for managing obesity and CVD and improving quality of life in patients with HFpEF & obesity.

Watch this video for perspective on the data presented at #AHA24. #cardiology